Intercept Pharmaceuticals Inc

+1.34 (+8.15%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)567.52M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$92.61 Million
Adjusted EPS-$1.04
See more estimates
10-Day MA$16.73
50-Day MA$16.86
200-Day MA$17.41
See more pivots

Intercept Pharmaceuticals Inc Stock, NASDAQ:ICPT

10 Hudson Yards, 37th floor, New York, New York 10001
United States of America
Phone: +1.646.747.1000
Number of Employees: 498


Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.